ISA Pharmaceuticals BV:製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C10510)
◆英語タイトル:ISA Pharmaceuticals BV - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10510
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:25
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:オランダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
ISA Pharmaceuticals BV (ISA Pharmaceuticals) is a developer of synthetic therapeutic vaccines for the treatment of cancer and persistent viral infections. The company’s pipeline products include ISA101, an immunotherapeutic vaccine for cervical cancer; MyISA, a personalized immunotherapy based on neoantigens to eradicate cancer; ISA203, preferentially expressed antigen in melanoma for treating different types of cancers; and ISA204 for the treatment of hepatitis B. It also develops synthetic long peptides technology used in the applications of viral and non-viral targets and provides multiple products for persistent virus infections. The company also provides amplivant technology, which is based on a proprietary and synthetic toll-like receptor agonist and is used in new generation immunotherapeutic for treating various diseases. ISA Pharmaceuticals is headquartered in Leiden, the Netherlands.

ISA Pharmaceuticals BV – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
ISA Pharma Raises US$10 Million In Venture Financing 10
Partnerships 11
Regeneron Pharma and ISA Pharma Enter into Partnership 11
ISA Therapeutics Enters into R&D Agreement with Shin Nippon Biomedical Labs 12
Licensing Agreements 13
Scancell Enters into Licensing Agreement with ISA Pharma 13
ISA Pharmaceuticals BV – Key Competitors 14
ISA Pharmaceuticals BV – Key Employees 15
ISA Pharmaceuticals BV – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Recent Developments 17
Corporate Communications 17
May 23, 2018: ISA Pharmaceuticals Promotes Gerben Moolhuizen to Chief Executive Officer 17
Product News 18
05/23/2017: Updated Results of Cervical Cancer Study Sponsored by ISA Pharmaceuticals to Be Presented at ASCO 2017 18
04/30/2018: ISA Pharmaceuticals Appoints Leon Hooftman as Chief Medical Officer 19
02/16/2017: Results of Cervical Cancer Study Sponsored by ISA Pharmaceuticals to Be Presented at ASCO-SITC 20
Clinical Trials 21
Apr 26, 2018: ISA Pharmaceuticals’ ISA101 Studied in Phase II Oropharyngeal Cancer Combination Trial at MD Anderson Cancer Center 21
Sep 11, 2017: Combined Therapy with Nivolumab and ISA 101 Vaccine Results in Promising Efficacy in HPV-positive Oropharyngeal Cancer 22
Sep 04, 2017: Results of Phase II Combination Trial of ISA101 and Nivolumab to be Presented at ESMO 2017 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare, Key Facts 2
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ISA Pharmaceuticals BV, Deals By Therapy Area, 2012 to YTD 2018 8
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
ISA Pharma Raises US$10 Million In Venture Financing 10
Regeneron Pharma and ISA Pharma Enter into Partnership 11
ISA Therapeutics Enters into R&D Agreement with Shin Nippon Biomedical Labs 12
Scancell Enters into Licensing Agreement with ISA Pharma 13
ISA Pharmaceuticals BV, Key Competitors 14
ISA Pharmaceuticals BV, Key Employees 15
ISA Pharmaceuticals BV, Subsidiaries 16

List of Figures
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ ISA Pharmaceuticals BV:製薬・医療:M&Aディール及び事業提携情報(ISA Pharmaceuticals BV - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆